ERBB2 and neoplasm: Furthermore, incorporating biological and microenvironmental markers (e.g., HER2-low/zero conversion, Ki-67, TILs, PIK3CA/TP53 status) alongside emerging circulating tumour DNA (ctDNA) minimal residual disease tests may support the development of multi-modal prognostic models that outperform single-parameter tools.